Atlas Trials

Cabazitaxel Versus the Switch to Alternative AR Targeted Therapy Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Primary Resistant Patients to Abiraterone or Enzalutamide

Clinical trial NCT02379390 · TERMINATED

Trial details

NCT number
NCT02379390
Sponsor
Sanofi
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Prostate Cancer Metastatic
Start date
2015-06-17
Primary completion
2018-05-10
Enrollment
8

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.